Key Highlights

  • Third quarter Revenue of USD 10.2 million rose 49% and topped the USD 7.4 million estimate; core revenue grew 27%.
  • The company agreed to acquire Akron, a supplier of GMP-grade reagents, with projected 2026 revenue of USD 28 million.
  • Full-year revenue guidance rose to at least USD 34.5 million, up from a USD 30 million to 32 million range.
  • Loss per share narrowed to USD 0.05 against an estimated loss of USD 0.08, per the supplied estimates.

MaxCyte (NASDAQ:MXCT) reported third quarter 2026 revenue of USD 10.2 million, up 49% from USD 6.8 million a year earlier and above the USD 7.4 million analyst estimate. Loss per share was USD 0.05, compared with an estimated loss of USD 0.08. Alongside the results, the cell therapy tools company announced a definitive agreement to acquire Akron from Arkline Investment Management, which chief executive Maher Masoud called one of the most exciting moments in the company's history.

Core revenue was USD 8.2 million, up 27% from USD 6.4 million, and program-related revenue from strategic platform license partners was USD 2.0 million, made up of a USD 1.0 million milestone tied to pivotal trial dosing and USD 1.0 million of commercial royalties. Instrument revenue rose to USD 2.8 million from USD 1.4 million, which management attributed partly to purchases by one partner that had been planned for the fourth quarter. For the nine months, the company reported revenue of USD 27.1 million and a net loss of USD 18.4 million.

The Akron Acquisition

Akron supplies GMP-grade reagents and ancillary materials used in cell therapy manufacturing, including cytokines, growth factors, culture media and cryopreservation solutions. Management said its products are written into customers' regulatory filings, and that Akron supports four commercially approved therapies and four additional programs on registrational pathways. Akron revenue is projected at USD 28 million for 2026, against about USD 23 million in 2025, with EBITDA of roughly USD 7 million to USD 8 million and positive cash flow.

On a pro forma basis, the combined company is projected to generate more than USD 60 million of revenue in 2026, nearly double MaxCyte's standalone base. Management said about 30% of combined revenue would come from commercial-stage customers, and that the largest customer would drop to roughly 14% of combined revenue from 27% on a standalone basis. It also cited about USD 3 million to USD 4 million of possible cost efficiencies.

Financing details appear in the quarterly filing: the company plans an initial draw of USD 20.0 million from a term Loan and USD 2.0 million from a revolver at closing. The term loan carries interest at the secured overnight financing rate plus 5.25%, with a 2.00% floor.

Guidance and Partner Programs

Total 2026 revenue is now projected at no less than USD 34.5 million, up from roughly USD 34 million cited in October and from a prior range of USD 30 million to USD 32 million. Management said the increase reflects accelerated instrument purchases, broader core strength and faster program advancement, and projects core revenue growth of about 15% in the second half.

Management also pointed to Vertex's reported CASGEVY revenue of about USD 99 million for the third quarter, which relies on MaxCyte technology, and said the company now supports more pivotal trials than ever, with up to three approved products possible within 24 months.

Integration and Program Milestones to Watch

The filing notes that the Acquisition carries closing conditions and integration risks, and the company's own risk section addresses them. Readers tracking the story can follow the closing date, the draw on the term loan and revolver, and cross-selling between the two customer bases, which overlap by roughly 10% today.

Other markers include pivotal-trial milestones at strategic platform license partners and the second-half core revenue trend against the 15% growth projection.